Daniel Gaudet

机构：Université du Québec à Chicoutimi, Brigham and Women's Hospital, Louisiana-Pacific (Canada), Cégep de Chicoutimi, Thrombolysis in Myocardial Infarction Study Group, Université de Montréal · ORCID：0000-0002-5185-3666

发表论文 642 篇 · 总被引 35586 次 · h-index 88

代表论文

• Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk (2025 · New England Journal of Medicine · 被引 55)
• Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial (2025 · The Lancet Diabetes & Endocrinology · 被引 22)
• Brief communication: Strong concordance of the North American Familial Chylomicronemia Syndrome Score with a positive genetic diagnosis in patients from the Balance study (2025 · Journal of clinical lipidology · 被引 5)
• Course of Pregnancy in a Woman With Familial Chylomicronemia Syndrome Treated With Plozasiran, a Small Interfering RNA Against ApoC3 (2025 · JIMD Reports · 被引 2)
• Clinical considerations for the treatment of patients with familial chylomicronemia syndrome using a hepatic-targeted APOC3 antisense oligonucleotide (2025 · American Journal of Preventive Cardiology · 被引 2)
• 26-A-10903-ACC APOLIPOPROTEIN C-III (APOC3) INHIBITION IN PATIENTS WITH VERSUS WITHOUT BASELINE FIBRATE USE (2026 · Journal of the American College of Cardiology · 被引 1)